Integrative vision in cancer research, prevention and therapy

IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE
Ashok DB. Vaidya M.D.,Ph.D.
{"title":"Integrative vision in cancer research, prevention and therapy","authors":"Ashok DB. Vaidya M.D.,Ph.D.","doi":"10.1016/j.jaim.2023.100856","DOIUrl":null,"url":null,"abstract":"<div><p>There is already a significant global initiative to explore the synergy between traditional medicine (TM) and oncology, for holistic best care of cancer patients. Integrative oncology clinics have emerged with operational efficiency. What is needed now is an integrative vision that inspires to seamlessly coordinate the <em>trans</em>-system efforts in cancer research and rapidly translate the positive outcomes into prevention and treatment of cancer. The current dominant paradigm to consider TM only for complementary and alternative adjunct usage cannot inspire state-of-the art research and development on TM leads and serendipitous discoveries. Ayurvedic concepts of <em>Vyadhi-kshamatwa</em> (Immune resistance), <em>Shatkriyakala</em> (Six stages of a disease) and <em>Hetuviparya Chikitsa</em> (Reversal of pathogenetic factors) need to be synergized with ayurvedic pharmacoepidemiology, reverse pharmacology, observational therapeutics, ayurgenomics, ayurvedic biology, and reverse ayurceutics. Such a paradigm-shifting vision may lead to pragmatic translational research/practice and system obstacles and novel bridges in Integrative Oncology.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947623001730/pdfft?md5=b8f201dcaf2557f86b4235e41989a995&pid=1-s2.0-S0975947623001730-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ayurveda and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0975947623001730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

There is already a significant global initiative to explore the synergy between traditional medicine (TM) and oncology, for holistic best care of cancer patients. Integrative oncology clinics have emerged with operational efficiency. What is needed now is an integrative vision that inspires to seamlessly coordinate the trans-system efforts in cancer research and rapidly translate the positive outcomes into prevention and treatment of cancer. The current dominant paradigm to consider TM only for complementary and alternative adjunct usage cannot inspire state-of-the art research and development on TM leads and serendipitous discoveries. Ayurvedic concepts of Vyadhi-kshamatwa (Immune resistance), Shatkriyakala (Six stages of a disease) and Hetuviparya Chikitsa (Reversal of pathogenetic factors) need to be synergized with ayurvedic pharmacoepidemiology, reverse pharmacology, observational therapeutics, ayurgenomics, ayurvedic biology, and reverse ayurceutics. Such a paradigm-shifting vision may lead to pragmatic translational research/practice and system obstacles and novel bridges in Integrative Oncology.

癌症研究、预防和治疗的综合视角。
在全球范围内,已经有很多人开始探索传统医学(TM)与肿瘤学之间的协同作用,以便为癌症患者提供全面的最佳治疗。中西医结合肿瘤诊所已经出现,并取得了良好的运营效果。现在需要的是一种综合性的愿景,它能激发人们无缝协调癌症研究中的跨系统工作,并迅速将积极成果转化为癌症预防和治疗。目前的主流模式认为 TM 仅用于补充和替代辅助用途,这无法激发对 TM 线索和偶然发现的最新研究和开发。阿育吠陀的 Vyadhi-kshamatwa(免疫抗性)、Shatkriyakala(疾病的六个阶段)和 Hetuviparya Chikitsa(致病因素的逆转)概念需要与阿育吠陀药物流行病学、逆向药理学、观察治疗学、阿育吠陀基因组学、阿育吠陀生物学和逆向阿育吠陀治疗学协同作用。这种范式转换愿景可能会带来实用的转化研究/实践,并为中西医结合肿瘤学带来系统障碍和新的桥梁。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Ayurveda and Integrative Medicine
Journal of Ayurveda and Integrative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
4.70
自引率
12.50%
发文量
136
审稿时长
30 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信